<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423435</url>
  </required_header>
  <id_info>
    <org_study_id>533-CL-006</org_study_id>
    <nct_id>NCT01423435</nct_id>
  </id_info>
  <brief_title>Study to Compare Pharmacokinetic Profiles of TRK-100STP in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males</brief_title>
  <official_title>A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the pharmacokinetics and safety of TRK-100STP in Japanese, Chinese, and
      South Korean non-elderly healthy adult males.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of pharmacokinetic parameters of TRK-100STP such as maximum observed concentration (Cmax), area under the serum concentration-time curve (AUC) and terminal half-life (t1/2)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, 12-lead electrocardiograms (ECGs) and lab tests</measure>
    <time_frame>Up to 6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Adult Male</condition>
  <condition>Pharmacokinetics of TRK-100-STP</condition>
  <arm_group>
    <arm_group_label>Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>South Korean</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRK-100STP</intervention_name>
    <description>oral</description>
    <arm_group_label>Japanese</arm_group_label>
    <arm_group_label>Chinese</arm_group_label>
    <arm_group_label>South Korean</arm_group_label>
    <other_name>beraprost</other_name>
    <other_name>Careload LA</other_name>
    <other_name>YM533</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: =&lt;50.0 to 80.0&gt; kg

          -  BMI: =&lt;17.6 to 26.4&gt;

          -  Subjects whose condition an investigator/subinvestigator has confirmed to be healthy
             by the date of drug administration, based on the screening test results

        Exclusion Criteria:

          -  Subjects who received an investigational drug within 120 days prior to the screening
             test in other clinical trials or post-marketing studies

          -  Subjects who had 400 mL whole blood drawing within 90 days prior to the screening
             test, who had 200 mL whole blood drawing within 30 days prior to the screening test,
             or had component blood drawing within 14 days prior to the screening test

          -  Subjects who has received or will receive any drug treatment including over the
             counter (OTC) drugs within 7 days prior to the day of confinement

          -  Subjects whose vital signs are out of the standard level in one of the following
             parameters at the time of the screening test or the day of confinement: blood
             pressure, pulse rate, body temperature, and 12-lead ECG

          -  Subjects who have had upper Gastro-Intestinal (GI) symptoms within 7 days prior to the
             day of confinement (1 day prior to the drug administration): nausea, vomiting, or
             stomachache

          -  Subjects who have complications or history of liver diseases: viral hepatitis or
             chronic bronchitis

          -  Subjects who have complications or history of Cardio Vascular (CV) diseases: chronic
             heart failure, angina, or arrythmia that needs treatment

          -  Subjects who have complications or history of respiratory diseases: severe bronchial
             asthma or chronic bronchitis. History of pediatric asthma is not included

          -  Subjects who have complications or history of respiratory diseases: severe peptic
             ulceration or gastro-esophageal reflux disease. History of appendicitis is not
             included

          -  Subjects who have complications or history of renal diseases: acute renal failure,
             glomerulonephritis, or interstitial nephritis. History of calculus is not included

          -  Subjects who have complications or history of cerebrovascular diseases including
             cerebral infarction

          -  Subjects who have complications or history of malignant tumors

          -  Subjects in whom the daily amount of alcohol or smoking is excessive

          -  Subjects who have received beraprost
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>October 2, 2011</last_update_submitted>
  <last_update_submitted_qc>October 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK-100STP</keyword>
  <keyword>PK</keyword>
  <keyword>beraprost sodium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

